FR-135313
Drug type
Protein
- Listing at source
- Listed
- Drug type
- Protein
- Drug name
- FR-135313
- Molecular weight
- 542.72
- Structure (SMILES)
- C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)NC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O
- fk 228 reduced
- FK-228 (REDUCED)
- fr 135313
- Fr-135313
- Insuline glargine U100 (reduced)
- insuline glargine u100 reduced
- Reduced-Dose Daily Buserelin
- Reduced-dose HHT
- reduced-dose PTCy
- romidepsin reduced
- ROMIDEPSIN REDUCED
- CAS registry numbers
- 390745-19-4
- ChEMBL ID
- CHEMBL146250
- InChIKey
- MEJLVLMAJJRLCR-GCCNXGTGSA-N
- PubChem compound IDs
- 9828788
- FDA ingredient codes (UNII)
- 4MQ5UQAIB8
- First in class
- No
- Orphan designation
- No
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 6
- Polar surface area
- 142.7
- Calculated partition coefficient (ALogP)
- 0.89
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 6
- Heavy atoms
- 36
- Molecular formula
- C24H38N4O6S2
- Monoisotopic mass
- 542.22327729
- Natural product
- No
- Recorded assays
- 44
- Active assays
- 29
Active assay types
- Confirmatory
Related records
Trials (102)
- A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
- A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
- A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
- A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
- A Study to Assess the Safety of Adacel® Vaccine
- A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
- A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco
- A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
- Addiction Potential of Very Low Nicotine Filtered Little Cigars
- Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
- An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations
- Analgesic Strategies in Newborns Receiving Prostaglandin Therapy
- Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
- CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
- Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
- CNS Uptake of Intranasal Glutathione
- Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
- Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®